ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Posted: February 6, 2023 at 12:50 am

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 1, 2023 (the “Grant Date”), ORIC granted a total of 35,596 non-qualified stock options and 5,948 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2023.

More here:
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Related Posts